why choose us

First received: March 08, 2023

Clinical Trial: A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma

Brief Summary: This study will be conducted in 2 parts.The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.

Read more